{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:06:01Z","timestamp":1790269561566,"version":"4.1.0"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,11,1]],"date-time":"2014-11-01T00:00:00Z","timestamp":1414800000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,8,5]],"date-time":"2014-08-05T00:00:00Z","timestamp":1407196800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"funder":[{"name":"Telethon Italy","award":["GGP12237"],"award-info":[{"award-number":["GGP12237"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurobiology of Disease"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1016\/j.nbd.2014.07.013","type":"journal-article","created":{"date-parts":[[2014,8,6]],"date-time":"2014-08-06T02:15:09Z","timestamp":1407291309000},"page":"62-73","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":56,"special_numbering":"C","title":["Genetic and pharmacological evidence that G2019S LRRK2 confers a hyperkinetic phenotype, resistant to motor decline associated with aging"],"prefix":"10.1016","volume":"71","author":[{"given":"Francesco","family":"Longo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derya R.","family":"Shimshek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Greggio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Morari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nbd.2014.07.013_bb0005","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1038\/ng.175","article-title":"Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease","volume":"40","author":"Barrett","year":"2008","journal-title":"Nat. Genet."},{"key":"10.1016\/j.nbd.2014.07.013_bb0010","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1038\/cdd.2012.42","article-title":"(G2019S) LRRK2 activates MKK4-JNK pathway and causes degeneration of SN dopaminergic neurons in a transgenic mouse model of PD","volume":"19","author":"Chen","year":"2012","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.nbd.2014.07.013_bb0015","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1021\/ml300123a","article-title":"Brain penetrant LRRK2 inhibitor","volume":"3","author":"Choi","year":"2012","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.nbd.2014.07.013_bb0020","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3389\/fnmol.2014.00049","article-title":"LRRK2 kinase activity regulates synaptic vesicle trafficking and neurotransmitter release through modulation of LRRK2 macro-molecular complex","volume":"7","author":"Cirnaru","year":"2014","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.nbd.2014.07.013_bb0025","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/nrn2935","article-title":"The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease","volume":"11","author":"Cookson","year":"2010","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.nbd.2014.07.013_bb0030","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1042\/BJ20100784","article-title":"Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)\/Ser(935), disruption of 14-3-3 binding and altered cytoplasmic localization","volume":"430","author":"Dzamko","year":"2010","journal-title":"Biochem. J."},{"key":"10.1016\/j.nbd.2014.07.013_bb0035","doi-asserted-by":"crossref","first-page":"e39132","DOI":"10.1371\/journal.pone.0039132","article-title":"The IkappaB kinase family phosphorylates the Parkinson's disease kinase LRRK2 at Ser935 and Ser910 during Toll-like receptor signaling","volume":"7","author":"Dzamko","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.nbd.2014.07.013_bb0045","doi-asserted-by":"crossref","first-page":"9416","DOI":"10.1021\/jm301020q","article-title":"Discovery of highly potent, selective, and brain-penetrable leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors","volume":"55","author":"Estrada","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.nbd.2014.07.013_bb0040","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1021\/jm401654j","article-title":"Discovery of highly potent, selective, and brain-penetrant aminopyrazole leucine-rich repeat kinase 2 (LRRK2) small molecule inhibitors","volume":"57","author":"Estrada","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.nbd.2014.07.013_bb0050","doi-asserted-by":"crossref","first-page":"10322","DOI":"10.1073\/pnas.1203223109","article-title":"Roco kinase structures give insights into the mechanism of Parkinson disease-related leucine-rich-repeat kinase 2 mutations","volume":"109","author":"Gilsbach","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.nbd.2014.07.013_bb0060","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.nbd.2006.04.001","article-title":"Kinase activity is required for the toxic effects of mutant LRRK2\/dardarin","volume":"23","author":"Greggio","year":"2006","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.nbd.2014.07.013_bb0055","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1750-1326-6-6","article-title":"Leucine-rich repeat kinase 2 and alpha-synuclein: intersecting pathways in the pathogenesis of Parkinson's disease?","volume":"6","author":"Greggio","year":"2011","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.nbd.2014.07.013_bb0065","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.gde.2009.03.008","article-title":"The genetics of Parkinson's syndromes: a critical review","volume":"19","author":"Hardy","year":"2009","journal-title":"Curr. Opin. Genet. Dev."},{"key":"10.1016\/j.nbd.2014.07.013_bb0070","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s00415-009-0117-x","article-title":"The leucine rich repeat kinase 2 (LRRK2) G2019S substitution mutation. Association with Parkinson disease, malignant melanoma and prevalence in ethnic groups in Israel","volume":"256","author":"Hassin-Baer","year":"2009","journal-title":"J. Neurol."},{"key":"10.1016\/j.nbd.2014.07.013_bb0075","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S1474-4422(08)70117-0","article-title":"Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case\u2013control study","volume":"7","author":"Healy","year":"2008","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.nbd.2014.07.013_bb0080","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.nbd.2013.09.009","article-title":"Surprising behavioral and neurochemical enhancements in mice with combined mutations linked to Parkinson's disease","volume":"62","author":"Hennis","year":"2014","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.nbd.2014.07.013_bb0090","doi-asserted-by":"crossref","first-page":"4209","DOI":"10.1093\/hmg\/ddr348","article-title":"LRRK2 protein levels are determined by kinase function and are crucial for kidney and lung homeostasis in mice","volume":"20","author":"Herzig","year":"2011","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.nbd.2014.07.013_bb0085","doi-asserted-by":"crossref","first-page":"e36581","DOI":"10.1371\/journal.pone.0036581","article-title":"High LRRK2 levels fail to induce or exacerbate neuronal alpha-synucleinopathy in mouse brain","volume":"7","author":"Herzig","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.nbd.2014.07.013_bb0095","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/j.1471-4159.2006.04246.x","article-title":"Expression and localization of Parkinson's disease-associated leucine-rich repeat kinase 2 in the mouse brain","volume":"100","author":"Higashi","year":"2007","journal-title":"J. Neurochem."},{"key":"10.1016\/j.nbd.2014.07.013_bb0100","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1750-1326-7-25","article-title":"LRRK2 knockout mice have an intact dopaminergic system but display alterations in exploratory and motor co-ordination behaviors","volume":"7","author":"Hinkle","year":"2012","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.nbd.2014.07.013_bb0105","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1093\/hmg\/ddm080","article-title":"Apoptotic mechanisms in mutant LRRK2-mediated cell death","volume":"16","author":"Iaccarino","year":"2007","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.nbd.2014.07.013_bb0110","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1042\/BJ20070209","article-title":"LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity","volume":"405","author":"Jaleel","year":"2007","journal-title":"Biochem. J."},{"key":"10.1016\/j.nbd.2014.07.013_bb0115","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1006\/exnr.1998.6848","article-title":"Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat","volume":"152","author":"Kirik","year":"1998","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.nbd.2014.07.013_bb0120","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1097\/MIB.0b013e318281f454","article-title":"Genome-wide association study signal at the 12q12 locus for Crohn's disease may represent associations with the MUC19 gene","volume":"19","author":"Kumar","year":"2013","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.nbd.2014.07.013_bb0125","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/0014-2999(72)90086-6","article-title":"Morphine catalepsy in the rat: relation to striatal dopamine metabolism","volume":"19","author":"Kuschinsky","year":"1972","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.nbd.2014.07.013_bb0130","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1002\/jnr.22611","article-title":"Elevated tonic extracellular dopamine concentration and altered dopamine modulation of synaptic activity precede dopamine loss in the striatum of mice overexpressing human alpha-synuclein","volume":"89","author":"Lam","year":"2011","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.nbd.2014.07.013_bb0135","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1038\/nm.2199","article-title":"Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease","volume":"16","author":"Lee","year":"2010","journal-title":"Nat. Med."},{"key":"10.1016\/j.nbd.2014.07.013_bb0140","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1523\/JNEUROSCI.5604-09.2010","article-title":"Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S","volume":"30","author":"Li","year":"2010","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2014.07.013_bb0145","doi-asserted-by":"crossref","first-page":"e17153","DOI":"10.1371\/journal.pone.0017153","article-title":"Phosphorylation-dependent 14-3-3 binding to LRRK2 is impaired by common mutations of familial Parkinson's disease","volume":"6","author":"Li","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.nbd.2014.07.013_bb0150","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.neuron.2009.11.006","article-title":"Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein","volume":"64","author":"Lin","year":"2009","journal-title":"Neuron"},{"key":"10.1016\/j.nbd.2014.07.013_bb0155","doi-asserted-by":"crossref","first-page":"3933","DOI":"10.1093\/hmg\/ddr312","article-title":"Inhibitors of LRRK2 kinase attenuate neurodegeneration and Parkinson-like phenotypes in Caenorhabditis elegans and Drosophila Parkinson's disease models","volume":"20","author":"Liu","year":"2011","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.nbd.2014.07.013_bb0160","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1093\/molbev\/msl114","article-title":"The Parkinson disease gene LRRK2: evolutionary and structural insights","volume":"23","author":"Marin","year":"2006","journal-title":"Mol. Biol. Evol."},{"key":"10.1016\/j.nbd.2014.07.013_bb0170","doi-asserted-by":"crossref","first-page":"6659","DOI":"10.1523\/JNEUROSCI.0987-04.2004","article-title":"Blockade of nociceptin\/orphanin FQ receptor signaling in rat substantia nigra pars reticulata stimulates nigrostriatal dopaminergic transmission and motor behavior","volume":"24","author":"Marti","year":"2004","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2014.07.013_bb0165","doi-asserted-by":"crossref","first-page":"9591","DOI":"10.1523\/JNEUROSCI.2546-05.2005","article-title":"Blockade of nociceptin\/orphanin FQ transmission attenuates symptoms and neurodegeneration associated with Parkinson's disease","volume":"25","author":"Marti","year":"2005","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2014.07.013_bb0175","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1523\/JNEUROSCI.4346-06.2007","article-title":"The nociceptin\/orphanin FQ receptor antagonist J-113397 and L-DOPA additively attenuate experimental parkinsonism through overinhibition of the nigrothalamic pathway","volume":"27","author":"Marti","year":"2007","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2014.07.013_bb0180","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.tins.2006.03.006","article-title":"LRRK2 in Parkinson's disease: protein domains and functional insights","volume":"29","author":"Mata","year":"2006","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.nbd.2014.07.013_bb0185","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.neuron.2012.08.022","article-title":"LRRK2 controls an EndoA phosphorylation cycle in synaptic endocytosis","volume":"75","author":"Matta","year":"2012","journal-title":"Neuron"},{"key":"10.1016\/j.nbd.2014.07.013_bb0195","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.neuroscience.2007.05.027","article-title":"A comparative analysis of leucine-rich repeat kinase 2 (Lrrk2) expression in mouse brain and Lewy body disease","volume":"147","author":"Melrose","year":"2007","journal-title":"Neuroscience"},{"key":"10.1016\/j.nbd.2014.07.013_bb0190","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.nbd.2010.07.010","article-title":"Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice","volume":"40","author":"Melrose","year":"2010","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.nbd.2014.07.013_bb0200","doi-asserted-by":"crossref","first-page":"e77198","DOI":"10.1371\/journal.pone.0077198","article-title":"LRRK2 affects vesicle trafficking, neurotransmitter extracellular level and membrane receptor localization","volume":"8","author":"Migheli","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.nbd.2014.07.013_bb0205","doi-asserted-by":"crossref","first-page":"E34","DOI":"10.1073\/pnas.1312701111","article-title":"Parkinson-related LRRK2 mutation R1441C\/G\/H impairs PKA phosphorylation of LRRK2 and disrupts its interaction with 14-3-3","volume":"111","author":"Muda","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.nbd.2014.07.013_bb0210","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1042\/BJ20091035","article-title":"Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease","volume":"424","author":"Nichols","year":"2009","journal-title":"Biochem. J."},{"key":"10.1016\/j.nbd.2014.07.013_bb0215","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.neuron.2004.10.023","article-title":"Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease","volume":"44","author":"Paisan-Ruiz","year":"2004","journal-title":"Neuron"},{"key":"10.1016\/j.nbd.2014.07.013_bb0220","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/nn.3636","article-title":"LRRK2 regulates synaptogenesis and dopamine receptor activation through modulation of PKA activity","volume":"17","author":"Parisiadou","year":"2014","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.nbd.2014.07.013_bb0225","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1523\/JNEUROSCI.3730-10.2011","article-title":"LRRK2 controls synaptic vesicle storage and mobilization within the recycling pool","volume":"31","author":"Piccoli","year":"2011","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2014.07.013_bb0230","doi-asserted-by":"crossref","first-page":"e18568","DOI":"10.1371\/journal.pone.0018568","article-title":"Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2","volume":"6","author":"Ramonet","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.nbd.2014.07.013_bb0235","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/bjp.2008.96","article-title":"Neuropeptide S is a stimulatory anxiolytic agent: a behavioural study in mice","volume":"154","author":"Rizzi","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.nbd.2014.07.013_bb0240","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1385-299X(97)00034-2","article-title":"An automated rotarod method for quantitative drug-free evaluation of overall motor deficits in rat models of parkinsonism","volume":"2","author":"Rozas","year":"1997","journal-title":"Brain Res. Brain Res. Protocol."},{"key":"10.1016\/j.nbd.2014.07.013_bb0245","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1037\/0735-7044.102.5.748","article-title":"The catalepsy test: its ups and downs","volume":"102","author":"Sanberg","year":"1988","journal-title":"Behav. Neurosci."},{"key":"10.1016\/j.nbd.2014.07.013_bb0250","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0163-7258(02)00191-2","article-title":"The novel and specific Rho-kinase inhibitor (S)-(+)-2-methyl-1-[(4-methyl-5-isoquinoline)sulfonyl]-homopiperazine as a probing molecule for Rho-kinase-involved pathway","volume":"93","author":"Sasaki","year":"2002","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.nbd.2014.07.013_bb0255","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0014-4886(79)90003-7","article-title":"Excessive bracing reactions and their control by atropine and L-DOPA in an animal analog of Parkinsonism","volume":"64","author":"Schallert","year":"1979","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.nbd.2014.07.013_bb0260","doi-asserted-by":"crossref","first-page":"164ra161","DOI":"10.1126\/scitranslmed.3004485","article-title":"Ser1292 autophosphorylation is an indicator of LRRK2 kinase activity and contributes to the cellular effects of PD mutations","volume":"4","author":"Sheng","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.nbd.2014.07.013_bb0265","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1523\/JNEUROSCI.2712-13.2014","article-title":"Mutant LRRK2 toxicity in neurons depends on LRRK2 levels and synuclein but not kinase activity or inclusion bodies","volume":"34","author":"Skibinski","year":"2014","journal-title":"J. Neurosci."},{"key":"10.1016\/j.nbd.2014.07.013_bb0270","doi-asserted-by":"crossref","first-page":"18676","DOI":"10.1073\/pnas.0508052102","article-title":"Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration","volume":"102","author":"Smith","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.nbd.2014.07.013_bb0275","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1002\/mds.23356","article-title":"Dopamine turnover increases in asymptomatic LRRK2 mutations carriers","volume":"25","author":"Sossi","year":"2010","journal-title":"Mov. Disord."},{"key":"10.1016\/j.nbd.2014.07.013_bb0280","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.bbapap.2005.06.015","article-title":"Development of specific Rho-kinase inhibitors and their clinical application","volume":"1754","author":"Tamura","year":"2005","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.nbd.2014.07.013_bb0285","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/bies.200900163","article-title":"Mechanisms in dominant parkinsonism: the toxic triangle of LRRK2, alpha-synuclein, and tau","volume":"32","author":"Taymans","year":"2010","journal-title":"Bioessays"},{"key":"10.1016\/j.nbd.2014.07.013_bb0290","doi-asserted-by":"crossref","first-page":"14622","DOI":"10.1073\/pnas.0906334106","article-title":"R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice","volume":"106","author":"Tong","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.nbd.2014.07.013_bb0295","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.1016\/j.bmcl.2013.05.054","article-title":"Discovery of novel indolinone-based, potent, selective and brain penetrant inhibitors of LRRK2","volume":"23","author":"Troxler","year":"2013","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.nbd.2014.07.013_bb0300","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.nbd.2008.02.011","article-title":"Nociceptin\/orphanin FQ receptor blockade attenuates MPTP-induced parkinsonism","volume":"30","author":"Viaro","year":"2008","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.nbd.2014.07.013_bb0305","doi-asserted-by":"crossref","first-page":"16842","DOI":"10.1073\/pnas.0507360102","article-title":"Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity","volume":"102","author":"West","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.nbd.2014.07.013_bb0310","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1042\/BST20120093","article-title":"LRRK2 GTPase dysfunction in the pathogenesis of Parkinson's disease","volume":"40","author":"Xiong","year":"2012","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.nbd.2014.07.013_bb0315","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1002\/mds.23737","article-title":"Genetic LRRK2 models of Parkinson's disease: dissecting the pathogenic pathway and exploring clinical applications","volume":"26","author":"Yue","year":"2011","journal-title":"Mov. Disord."},{"key":"10.1016\/j.nbd.2014.07.013_bb0320","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa0903753","article-title":"Genomewide association study of leprosy","volume":"361","author":"Zhang","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.nbd.2014.07.013_bb0325","doi-asserted-by":"crossref","first-page":"753","DOI":"10.7150\/ijbs.7.753","article-title":"Temporal expression of mutant LRRK2 in adult rats impairs dopamine reuptake","volume":"7","author":"Zhou","year":"2011","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.nbd.2014.07.013_bb0330","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.neuron.2004.11.005","article-title":"Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology","volume":"44","author":"Zimprich","year":"2004","journal-title":"Neuron"}],"container-title":["Neurobiology of Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969996114002149?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969996114002149?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:23:58Z","timestamp":1538353438000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969996114002149"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":66,"alternative-id":["S0969996114002149"],"URL":"https:\/\/doi.org\/10.1016\/j.nbd.2014.07.013","relation":{},"ISSN":["0969-9961"],"issn-type":[{"value":"0969-9961","type":"print"}],"subject":[],"published":{"date-parts":[[2014,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genetic and pharmacological evidence that G2019S LRRK2 confers a hyperkinetic phenotype, resistant to motor decline associated with aging","name":"articletitle","label":"Article Title"},{"value":"Neurobiology of Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nbd.2014.07.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}